Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of YBSW015 in Healthy Subjects
NCT05369754Phase 1Unknown
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of YBSW015 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoints: Safety of YBSW015 injection up to 85 days and Tolerability of YBSW015 injection up to 85 days. Status: unknown.
02
Drugs
YBSW015
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05369754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369754.